Table 1 Active Clinical Trials with the 3 most developed PARP1 inhibitors.
From: Treatment options for patients with triple-negative breast cancer
Number | Population studied | Description |
|---|---|---|
Olaparib | ||
NCT01116648 | Metastatic TNBC | Phase I/II study to evaluate optimal drug dose and establish activity of cediranib and olaparib. |
NCT01078662 | BRCA associated breast cancer | Phase II in patients with BRCA related cancers |
NCT01115829 | Metastatic TNBC | Phase 1 of the combination of cediranib plus olaparib followed by a randomized phase 2 that evaluates cediranib with or without olaparib. |
NCT00516724 | Metastatic TNBC | Multi-arm Phase I study that evaluates the safety and efficacy of the combination of olaparib with carboplatin, olaparib with paclitaxel or olaparib with carboplatin and paclitaxel. |
NCT00647062 | Metastatic TNBC or BRCA associated breast cancer | Phase 1 of the combination of olaparib and carboplatin |
Veliparib | ||
NCT01104259 | Metastatic TNBC or BRCA associated cancer | Phase I study of the combination of veliparib, vinorelbin and cisplatin |
NCT01149083 | BRCA associated breast cancer | Randomized phase 2 evaluating veliparib with or without carboplatin. |
NCT01042379 | Neoadjuvant TNBC | Multi-arm study that evaluates several regimens, One arm contains the combination of paclitaxel, carboplatin and veliparib |
Iniparib | ||
NCT00813956 | Neoadjuvant TNBC | Phase 2 study of the combination of gemcitabine, carboplatin and iniparib. |
NCT01204125 | Neoadjuvant TNBC | Randomized phase 2 study of paclitaxel with or without iniparib |
NCT01173497 | TNBC with brain metastasis | Phase 2 study of iniparib and irinotecan in women with CNS metastasis. |